RVMD - Revolution Medicines, Inc.
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
Revolution Medicines has taken a new approach to the treatment of certain cancers. The company's lead product is approaching the regulatory review stage.
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC).
Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year.
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany.
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee Therapeutics, signals buyers are willing to pay up for de-risked clinical assets in oncology, obesity, and cell therapy.
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D.
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.
Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Can the drugmaker justify its valuation?
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Revolution Medicines (RVMD) moved higher in US premarket trading after fresh data added more weight to the story around daraxonrasib, its experimental pancreati